K-numberK251999
Device namePromogran Prisma™ Collagen Matrix with ORC and Silver
ApplicantSolventum Germany GmbH
Product codeFRO
Device classClass U
Decision dateMar 13, 2026
DecisionSubstantially Equivalent
Regulation
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Promogran Prisma™ Collagen Matrix with ORC and Silver is a sterile, freeze-dried wound dressing composed of 44% oxidized regenerated cellulose, 55% collagen, and 1% silver. It transforms into a soft gel in the presence of wound exudate and can be used alone with a secondary dressing or in combination with the ActiV.A.C. Negative Pressure Wound Therapy System for management of various wound types including diabetic ulcers, venous ulcers, pressure ulcers, burns, and traumatic wounds.

Technological characteristics

The subject device shares identical indications for use, operating principles, sterilization method (gamma irradiation at 10⁻⁶ SAL), packaging, shelf-life (2 years), wound sizes, care settings, and dressing material composition with the predicate device. The primary difference is the addition of compatibility with V.A.C.® Peel and Place Dressings in conjunction with ActiV.A.C. Negative Pressure Wound Therapy, whereas the predicate used V.A.C.® Granufoam and V.A.C.® Simplace Dressings.

Test standards cited

ISO 11137 (gamma irradiation sterilization); ISO 13485 (quality management system requirements cited for design controls, nonconforming product handling, and corrective/preventative action).

Substantial equivalence argument

The subject device is substantially equivalent to the predicate because it maintains identical composition, indications for use, operating principles, and technological characteristics. The extension to include V.A.C.® Peel and Place Dressing compatibility does not introduce new safety concerns, as simulated use testing confirmed the dressing does not inhibit negative pressure delivery, biocompatibility was previously established, and human factors testing confirmed the revised instructions for use are safe and effective.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →